CNTB - Connect Biopharma

-

$undefined

N/A

(N/A)

Connect Biopharma NasdaqGM:CNTB Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is headquartered in San Diego, California.

Location: 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, 92130, United States | Website: https://www.connectbiopharm.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-39.72M

Cash

84.0M

Avg Qtr Burn

-8.245M

Short % of Float

0.53%

Insider Ownership

40.65%

Institutional Own.

43.97%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

Phase 1

Update

Failed

Discontinued

Rademikibart (CBP-201) (Th2 cell modulator) Details
Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps

Failed

Discontinued